---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-023946"
form_type: "8-K"
ticker: "PYXS"
cik: "0001782223"
company_name: "Pyxis Oncology, Inc."
filed_at: "2023-05-24T23:59:59+00:00"
generated_at: "2026-06-14T16:07:10.721437+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "low"
source: SEC EDGAR
---

# Pyxis Oncology announces acquisition of Apexigen; no deal terms disclosed

## Summary
- Pyxis Oncology and Apexigen held a joint investor call on May 24, 2023 to discuss the proposed business combination.
- Financial terms of the acquisition were not disclosed in the filing.
- The transaction is subject to customary closing conditions, including stockholder and regulatory approvals.
- Pyxis plans to file a registration statement on Form S-4 in connection with the deal.

## SEC filing metadata
- accession: 0000950170-23-023946
- form_type: 8-K
- ticker: PYXS
- cik: 0001782223
- company_name: Pyxis Oncology, Inc.
- filed_at: 2023-05-24T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: low
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1782223/000095017023023946/0000950170-23-023946-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1782223/000095017023023946/pyxs-20230524.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-023946
- JSON: https://secwatch.observer/filing/0000950170-23-023946.json
- Plain text: https://secwatch.observer/filing/0000950170-23-023946.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.